The present invention provides a method for treating behavioral and psychological symptoms in patients with dementia comprising administering an effective dose of pure 5-HT.sub.6 receptor antagonist and acetylcholinesterase inhibitor or NMDA receptor antagonist. The present invention also relates to a pharmaceutical combination comprising pure 5-HT.sub.6 receptor antagonist and acetylcholinesterase inhibitor or NMDA receptor antagonist, in particular for treating behavioral and psychological symptoms in patients with dementia. The present invention further provides use of the said compounds in the manufacture of a medicament, and a pharmaceutical composition comprising the said compounds intended for the treatment of disorders described herein.

The present invention provides a method for treating behavioral and psychological symptoms in patients with dementia comprising administering an effective dose of pure 5-HT.sub.6 receptor antagonist and acetylcholinesterase inhibitor or NMDA receptor antagonist. The present invention also relates to a pharmaceutical combination comprising pure 5-HT.sub.6 receptor antagonist and acetylcholinesterase inhibitor or NMDA receptor antagonist, in particular for treating behavioral and psychological symptoms in patients with dementia. The present invention further provides use of the said compounds in the manufacture of a medicament, and a pharmaceutical composition comprising the said compounds intended for the treatment of disorders described herein.

The present invention provides a method for treating behavioral and psychological symptoms in patients with dementia comprising administering an effective dose of pure 5-HT.sub.6 receptor antagonist and acetylcholinesterase inhibitor or NMDA receptor antagonist. The present invention also relates to a pharmaceutical combination comprising pure 5-HT.sub.6 receptor antagonist and acetylcholinesterase inhibitor or NMDA receptor antagonist, in particular for treating behavioral and psychological symptoms in patients with dementia. The present invention further provides use of the said compounds in the manufacture of a medicament, and a pharmaceutical composition comprising the said compounds intended for the treatment of disorders described herein.

A method of inducing psychedelic states in an individual, by administering mescaline, a salt thereof, analogs thereof, or derivatives thereof to the individual, and inducing a psychedelic state in the individual. A method of therapy, by administering an intermediate “good effect dose” of mescaline, salt of mescaline, analogs thereof, or derivatives thereof to an individual, and inducing positive acute drug effects that are known to be associated with more positive long-term responses in psychiatric patients. A method of therapy, by administering an “ego-dissolution” dose of mescaline, a salt of mescaline, analogs thereof, or derivatives thereof to an individual, and providing the experience of ego-dissolution.

The present invention provides for the treatment, prevention, and/or reduction of a risk of a disease, disorder, or condition in which aldehyde toxicity is implicated in the pathogenesis, including ocular disorders, skin disorders, conditions associated with injurious effects from blister agents, and autoimmune, inflammatory, neurological and cardiovascular diseases by the use of a primary amine to scavenge toxic aldehydes, such as MDA and HNE.

The present invention provides for the treatment, prevention, and/or reduction of a risk of a disease, disorder, or condition in which aldehyde toxicity is implicated in the pathogenesis, including ocular disorders, skin disorders, conditions associated with injurious effects from blister agents, and autoimmune, inflammatory, neurological and cardiovascular diseases by the use of a primary amine to scavenge toxic aldehydes, such as MDA and HNE.

The invention features the use of nitro-aminoadamantane compounds for the treatment and prophylaxis of severe symptoms of beta-coronavirus infections, such as infections by SARS-CoV-2, SARS-CoV-1, MERS-CoV, and related viruses.

The invention features the use of nitro-aminoadamantane compounds for the treatment and prophylaxis of severe symptoms of beta-coronavirus infections, such as infections by SARS-CoV-2, SARS-CoV-1, MERS-CoV, and related viruses.

Methods of treating mental disorders, including anxiety disorders such as obsessive-compulsive disorder, are provided. The methods comprise administering an effective amount of a glutamate modulator to an individual in need thereof. Also provided are methods of enhancing the activity of a serotonin reuptake inhibitor (SRI) comprising co-administering a glutamate modulator and a serotonin reuptake inhibitor. Pharmaceutical composition comprising a serotonin reuptake inhibitor and a glutamate modulator are also provided.

Methods of treating mental disorders, including anxiety disorders such as obsessive-compulsive disorder, are provided. The methods comprise administering an effective amount of a glutamate modulator to an individual in need thereof. Also provided are methods of enhancing the activity of a serotonin reuptake inhibitor (SRI) comprising co-administering a glutamate modulator and a serotonin reuptake inhibitor. Pharmaceutical composition comprising a serotonin reuptake inhibitor and a glutamate modulator are also provided.